Back to event
Federal RegisterGovernmentRegulationMedicareDrug PricingInflation Reduction ActPrescription Drug Benefit
Medicare Drug Price Negotiation Program and Medicare Prescription Drug Benefit Program
By Medicaid Services, Human Services Department, Centers for Medicare, Health · Nov 8, 2026, 11:00 PM CST
Read full article at Federal Register
This rule finalizes and codifies the Medicare Drug Price Negotiation Program ("Negotiation Program") and establishes certain new policies for the Negotiation Program and the Medicare Prescription Drug Benefit Program ("Part D Program") as required by the Inflation Reduction Act of 2022. This final rule also finalizes a proposed policy for specific fixed combination drugs that are new formulations.
Excerpt shown under fair-use limits. Full text remains with the original publisher.
People in this coverage
Explore their history and attributable record. Being mentioned does not imply endorsement.
Layer 1 · Claims & fact checks
AI analysisOpinion vs. reporting
AI analysisThe document is a factual regulatory announcement without opinion; it reports the content of the final rule.